Announcements Trials
Browse Landscape

Phase

Phase 2 5

Status

Completed 5

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5

Conditions

Prostatic Neoplasms 5Pain 1

Interventions

Cyclophosphamide 517Bevacizumab 488Carboplatin 424pembrolizumab 388Paclitaxel 385Gemcitabine 372Cisplatin 366Docetaxel 323Rituximab 316Radiotherapy 296Nivolumab 247Doxorubicin 243Dexamethasone 240Fluorouracil 225Capecitabine 214Oxaliplatin 211Erlotinib Hydrochloride 206fludarabine phosphate 201Etoposide 188Cetuximab 186Lenalidomide 177Pemetrexed 176Bortezomib 174Trastuzumab 173Filgrastim 171fludarabine 166Prednisone 166Leucovorin 166Cytarabine 166Irinotecan 161

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Has results × Radium-223 × Clear all
NCT04037358 2025-12-19

RAVENS

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
64 enrolled 25 charts
Genitourinary

Prostatic Neoplasms

NCT03093428 2025-03-28

Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC

Dana-Farber Cancer Institute

Phase 2 Completed
45 enrolled 12 charts
Genitourinary

Prostatic Neoplasms

NCT03002220 2024-12-11

EXCAAPE

MedSIR

Phase 2 Completed
52 enrolled 15 charts
Genitourinary

Prostatic Neoplasms

NCT02278055 2023-04-07

Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
29 enrolled 10 charts
Genitourinary

Pain, Prostatic Neoplasms

NCT02463799 2021-07-08

Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
36 enrolled 23 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡